About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

COMPLETEDPhase 2

Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines

A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Determine the Optimal Dose of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines

NCT00430586•Merz Pharmaceuticals GmbH

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Glabellar Frown Lines

Interventions

Botulinum neurotoxin type A, free of complexing proteins

Placebo

Locations

1

Germany

Locations (1)

Merz Pharmaceuticals GmbH

Frankfurt, Germany

Key Dates

Start Date

November 1, 2006

Completion Date

August 1, 2007

Last Updated

August 3, 2011

Related Studies

Active Not Recruiting

Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines

NCT05481931

Glabellar Frown Lines

COMPLETEDPhase 2

Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines

NCT06411002

Glabellar Frown Lines

COMPLETEDPhase 3

Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines

NCT05146999

Glabellar Frown Lines

COMPLETEDPhase 3

Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines

NCT05148000

Glabellar Frown LinesCanthal Lines

COMPLETEDPhase 4

Study Comparing Treatment With Alluzience vs Reconstituted Toxin

NCT05277337

Glabellar Frown Lines

COMPLETEDPhase 3

Treatment of Moderate to Severe Glabellar Lines

NCT04249583

Glabellar Frown Lines

View all related studies

Sponsors

Lead Sponsor

Merz Pharmaceuticals GmbH

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 3, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions